in vivo study

• 

  Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis

  11:39 AM | October 3, 2017

  Results of In Vivo Study Signifies Completion of another Critical Milestone in Company’s Phase I of NIAID Contract* to Develop ODS Strip for Anti-Tuberculosis Treatment Option OXNARD, Calif., Oct. 03, 2017, CURR, (GLOBE NEWSWIRE) — Oak Therapeutics, a subsidiary of CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, has completed an in vivo study that compared the pharmacokinetics of its proprietary 300mg Isoniazid (INH) oral dissolvable strip (ODS) as an anti-tuberculosis (TB) treatment option against an existing

  Read more

• Tuesday, October 28th – Penny Stock Market Wrap.

  2:29 AM | October 29, 2014

  ELRA NNAN & PSSS More Info @ Web Site: www.OTCMarkets.com Tuesday, October 28th – Follow us on Twitter @PUBLIC_WIRE GNOLF- UP 100% PSSS – UP 89% TPIV – UP 44% SUB PENNY GAINERS – ELRA +337%, NNAN +283%, VTEQ +112%, SVFC +100% and MRIB +71% Stocks that took a tumble today- XTRN down 40% ALCSQ down 33% LEXG, GLFH both down 26%

  Read more